Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings. In an analysis of data from more than 300,000 adults with type 2 diabetes registered in three medical databases in England and Wales, the use of an SGLT2 inhibitor alone or
United States Alisonk Wright European Association For The Study Of Diabetes Clinical Practice Research Datalink American Diabetes Association University Of Manchester School Medical Sciences
Source: healio.com